These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 29596951

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G, Institution Investigators.
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
    Shestakova MV, Suhareva OIu, Chernova TO, Shmushkovich IA, Aleksandrov AA, Il'in AV, Dedov II.
    Ter Arkh; 2013 Aug; 85(8):49-55. PubMed ID: 24137964
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
    Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Wang Y, Foley JE.
    Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Vildagliptin with metformin once-daily regimen-insights from a single-center analysis.
    Chatterjee S, Chatterjee S.
    Am J Ther; 2015 Apr; 22(3):195-8. PubMed ID: 23665884
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
    Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE.
    Diabetes Obes Metab; 2008 Aug; 10(8):675-82. PubMed ID: 18248490
    [Abstract] [Full Text] [Related]

  • 35. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
    Kanazawa I, Tanaka KI, Notsu M, Tanaka S, Kiyohara N, Koike S, Yamane Y, Tada Y, Sasaki M, Yamauchi M, Sugimoto T.
    Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
    [Abstract] [Full Text] [Related]

  • 36. DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes.
    Kozlovski P, Bhosekar V, Foley JE.
    Vasc Health Risk Manag; 2017 Jan; 13():123-126. PubMed ID: 28408838
    [Abstract] [Full Text] [Related]

  • 37. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
    Ayvaz G, Keskin L, Akin F, Dokmetas HS, Tasan E, Ar IB, Uren E, GALATA Study Group.
    Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.